Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul-Aug;15(4):102186.
doi: 10.1016/j.dsx.2021.102186. Epub 2021 Jun 27.

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

Ahmad Fariz Malvi Zamzam Zein  1 , Catur Setiya Sulistiyana  2 , Wilson Matthew Raffaelo  3 , Raymond Pranata  4
Affiliations
Meta-Analysis

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

Ahmad Fariz Malvi Zamzam Zein et al. Diabetes Metab Syndr. 2021 Jul-Aug.

Abstract

Aims: This systematic review and meta-analysis aims to investigate the effect of ivermectin on mortality in patients with COVID-19.

Methods: A comprehensive systematic literature search was performed using PubMed, Scopus, Embase, and Clinicaltrials.gov from the inception of databases up until April 9, 2021. The intervention group was ivermectin and the control group was standard of care or placebo. The primary outcome was mortality reported as risk ratio (RR).

Results: There were 9 RCTs comprising of 1788 patients included in this meta-analysis. Ivermectin was associated with decreased mortality (RR 0.39 [95% 0.20-0.74], p = 0.004; I2: 58.2%, p = 0.051). Subgroup analysis in patients with severe COVID-19 showed borderline statistical significance towards mortality reduction (RR 0.42 [95% 0.18-1.00], p = 0.052; I2: 68.3, p = 0.013). The benefit of ivermectin and mortality was reduced by hypertension (RR 1.08 [95% CI 1.03-1.13], p = 0.001); but was not influenced by age (p = 0.657), sex (p = 0.466), diabetes (p = 0.429). Sensitivity analysis using fixed-effect model showed that ivermectin decreased mortality in general (RR 0.43 [95% CI 0.29-0.62], p < 0.001) and severe COVID-19 subgroup (RR 0.48 [95% CI 0.32-0.72], p < 0.001).

Conclusions: Ivermectin was associated with decreased mortality in COVID-19 with a low certainty of evidence. Further adequately powered double-blinded placebo-controlled RCTs are required for definite conclusion.

Keywords: Coronavirus; Ivermectin; Mortality; SARS-CoV-2; Therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors have no potential conflict of interest.

Figures

Fig. 1
Fig. 1
Prisma flowchart.
Fig. 2
Fig. 2
Ivermectin and mortality.
Fig. 3
Fig. 3
Ivermectin and mortality (severe COVID-19 subgroup).
Fig. 4
Fig. 4
Risk of bias assessment.
Fig. 5
Fig. 5
Publication bias.
See this image and copyright information in PMC

References

    1. Who . 2021. Weekly epidemiological update - 2 March 2021. Geneva.
    1. Pranata R., Huang I., Raharjo S.B. Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Indian Pacing Electrophysiol J. 2020;20:193–198. doi: 10.1016/j.ipej.2020.08.001. - DOI - PMC - PubMed
    1. Lim M.A., Pranata R., Huang I., Yonas E., Soeroto A.Y., Supriyadi R. Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis. Can J Kidney Heal Dis. 2020;7 doi: 10.1177/2054358120938573. 2054358120938573. - DOI - PMC - PubMed
    1. Pranata R., Huang I., Lim M.A., Yonas E., Vania R., Kuswardhani R.A.T. Delirium and mortality in coronavirus disease 2019 (COVID-19) – a systematic review and meta-analysis. Arch Gerontol Geriatr. 2021;95:104388. doi: 10.1016/j.archger.2021.104388. - DOI - PMC - PubMed
    1. Huang I., Pranata R., Lim M.A., Oehadian A., Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14 doi: 10.1177/1753466620937175. - DOI - PMC - PubMed